KPTI Karyopharm Therapeutics Inc.

NEUTRAL Impact: 2/10 Insider Cluster (6 insiders)
Horizon weeks Filed May 15, 2026 Processed 14d 9h ago
Insider cluster: 6 insiders, $0.0M total
Latest settled — T+5d ⚠ clustered
KPTI ▲ +25.63% at T+5d
NEUTRAL call ✓ call won +25.63% · α vs SPY +24.01% · entry $7.14 → $8.97
Next anchor: T+20d in 5d
Last close $8.50 (close Jun 8) · +19.05% from $7.14 entry
Entry anchored
May 15, 03:59 PM ET
via Databento tick
T+1d
+4.62%
call +4.62% · α +5.27%
$7.47
settled 23d ago
T+5d
+25.63%
call +25.63% · α +24.01%
$8.97
settled 19d ago
T+20d
call — · α —
in 5d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Six KPTI insiders, including CEO Richard Paulson, sold shares on May 14 (the same day as Q1 earnings), totaling $35,000 in open-market sales. The dollar value is 0.02% of the $185M market cap — well below the 0.1% materiality floor. This is a routine cluster timed to a blackout-window opening, not an informed bearish signal. Separately, a director received a $0 grant of 15,508 shares on May 21 as non-cash compensation.

Key Financial Metrics

Direction
selling
Total Value
$35.0K
Insiders
6

Actionable Insight

These sales are trivial and routine — ignore them. The real risk for KPTI is the $400M shelf registration (200%+ dilution) and cash runway ending late Q3 2026. Watch for an equity offering or partnership announcement as the financing catalyst, not insider trading patterns.

Key Facts

  • Six insiders, including the CEO and CFO, sold shares on May 14 at $9.50, totaling $35,000.
  • Sales represent 0.02% of $185M market cap — immaterial by all proportionality standards.
  • Director Barry Greene received a 15,508-share $0 grant on May 21 (non-cash compensation).
  • Sales occurred on earnings day (Q1 2026 results filed May 14), consistent with a blackout-window opening.
  • Historical calibration shows cluster sell signals at this size have no predictive power for KPTI.

Financial Impact

Total insider sales of $35K, or ~0.02% of market cap; plus $0 non-cash grant

dilution

Risk Factors

  • $400M shelf registration filed May 4 creates massive potential dilution (~200% of current market cap).
  • Cash runway only extends into late Q3 2026 — acute financing risk constrains the stock.
  • Phase 3 SENTRY myelofibrosis trial missed a co-primary endpoint, creating pipeline uncertainty.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KPTI-1779826082813
11 reports for KPTI
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+20▲ +38.99%Mar 3, 2026
Filters
Rows
Reports for KPTI — sortable, filterable
Type Now
May 15, 2026
25d ago
Insider Cluster
NEUTRAL ★ 3/10
$7.14 $8.97▲ +25.63%▲ +24.01%$8.50 (+19.05%)
May 15, 2026
25d ago
Insider Cluster
NEUTRAL ★ 2/10
$7.14 $8.97▲ +25.63%▲ +24.01%$8.50 (+19.05%)
May 15, 2026
25d ago
Insider Cluster
BEARISH ★ 6/10
$7.14 $8.97▼ −25.63%▼ −24.01%$8.50 (−19.05%)
May 15, 2026
25d ago
Insider Cluster
NEUTRAL ★ 3/10
$7.14 $8.97▲ +25.63%▲ +24.01%$8.50 (+19.05%)
May 15, 2026
25d ago
Insider Cluster
BEARISH ★ 6/10
$7.14 $8.97▼ −25.63%▼ −24.01%$8.50 (−19.05%)
May 15, 2026
26d ago
EFFECT
BEARISH ★ 7/10
$7.67 $8.16▼ −6.39%▼ −5.43%$8.50 (−10.82%)
May 14, 2026
26d ago
8-K
MIXED ★ 6/10
$8.90 $8.06▼ −9.44%▼ −8.72%$8.50 (−4.49%)
May 4, 2026
5w ago
S-3
NEUTRAL ★ 3/10
$9.41 $8.81▼ −6.38%▼ −8.36%$8.50 (−9.67%)
May 4, 2026
5w ago
S-3
BEARISH ★ 7/10
$9.41 $8.92▲ +5.26%▲ +7.24%$8.50 (+9.67%)
Mar 3, 2026
14w ago
8-K
BEARISH ★ 8/10
$9.13 $8.23▲ +9.86%▲ +9.38%$8.50 (+6.90%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 8h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access